13 Crucial Actions To Protect Your Personal Finances During (And Before) A Divorce – 01/14/2022
Going through a divorce is an unquestionably stressful and emotional time in a person’s life. Regardless of the surrounding circumstances, protecting your personal finances should always be a priority.
If you’re preparing for divorce negotiations, it’s important to educate yourself about your financial options to ensure nothing is overlooked and you are getting the best possible settlement. To help, a panel of Forbes Finance Council members shared some essential financial steps people often overlook during a divorce. Here’s what they believe you should do and why each action is so important.
8. Don’t Forget About Car And Health Insurance
Make sure you look at the basics of who is going to get new car insurance and health insurance. There are lots of important big issues that need to be addressed, but sometimes the little things can have a big impact. – JD Morris, Red Hook Capital
Our goal is to find like minded people to co-invest with us through our SPVs. Contact us at jdm.networking@gmail.com or join us on LinkedIn!
Investor Network by JD (IN)
Join our group as we have invested in tools to help explore the best deals and this Friday are getting on of our returns for a SPV investment.
RECENT SAAS DEALS as 2021-01-27
Polly, a San Francisco-based SaaS technology company for mortgage capital markets, raised $37 million in Series B funding led by Menlo Ventures and was joined by investors including Movement Mortgage, First American Financial, FinVC, 8VC, Khosla Ventures and Fifth Wall.
Vesta, a San Francisco-based mortgage loan origination SaaS company, raised $30 million in Series A funding led by a16z and was joined by investors including Zigg Capital, Conversion Capital, and Bain Capital Ventures.
Darwinbox, a Hyderabad, India-based SaaS-based human management platform, raised $72 million in funding led by Technology Crossover Ventures, Meta Platforms, Spotify, Salesforce, Sequoia Capital India, and Lightspeed India.
RHC has co-invested in some amazing deals and funds. You can still co-invest alongside us into early-stage and other deals. For example, we are LPs in Social Leverage and are co-investing with them.
Social Leverage Capital Fund IV, LP, a $99M seed-stage fund focused on backing exceptional founders in the Fintech, Enterprise SaaS and Consumer space.
Since our inception in 2009, we have been seed-stage investors in some of the world’s leading startups, including Robinhood, eToro, Kustomer, and Manscaped, and have made investments in over 150 seed-stage companies to date. As our fund size has grown, so has our ability to invest additional capital as the portfolio raises later-stage capital.
Talk to us about our different investment strategies!
Members of the Red Hook Capital team will be in Jonathan Club Santa Monica Beach Club for meeting with people and entities (family office, SPV, etc.) during the month of June.
OPTIONS:
FUND: Meeting one of our fund managers and HNWI that in less than 90 days is having distribution back to our Hybrid Fund.
DO GOOD FUND: Meeting one of our fund managers for SPAC and fund that is helping solar and water projects worldwide. Did I say he also makes movies for fun and family office has been doing projects worldwide for over 30 years?
JUST FUN: Dinner with other HNWI hosted by one of our fund managers (and largest investor) at Jonathan Club’s Santa Monica Beach Club with other family offices and HNWI.
REQUIREMENTS:
Track record of co-investing with others to get returns;
Like minded investors that like to have fun (we had an amazing event at luxury car show at The Ritz-Carlton, Amelia Island);
Interview with RHC staff where we show you our PROOF of fund and investments with the understanding that you or your entity have $5 million invested in deals and are an active two-way investor (we invest in your deals and you invest in your deals).
Contact Sarah M at Sarah@RHC21.Fund or visit our staff on LinkedIn at Jack D or Charlette F anytime.
Outokumpu, , Lion Electric, TOD’S, and others coming soon!
Lottomatica Scommesse: International Game Technology PLC (NYSE:IGT) (“IGT”) announced that on May 10, 2021 its wholly-owned subsidiary, IGT Lottery S.p.A. (formerly Lottomatica Holding S.r.l.) (the “Seller”), completed the sale of 100% of the share capital of Lottomatica Videolot Rete S.p.A. PRESS RELEASE: International Game Technology PLC Announces Completion Of Sale Of Italian B2C Gaming Business | Nasdaq
DEAL VALUATION ( Lottomatica Scommesse )
The company, a subsidiary of Lottomatica Holding, was acquired by Gamenet, via its financial sponsor Apollo Global Management, for EUR 950 million on May 12, 2021.
DEAL LEADER ( International Game Technology PLC )
Fabio Cairoli, 54, is Chief Executive Officer, Italy, and is responsible for managing all business lines, marketing services, and sales for the Company’s Italian operations. Through his leadership of the largest lottery operator in the world, Mr. Cairoli shares insights and best practices with other organizations in the Company. Mr. Cairoli joined the Company in 2012 as Senior Vice President of Business. He has more than 20 years of experience in consumer goods for multinational organizations, with both local and international expertise. He served as Group General Manager and Board Member of Bialetti Industrie, a world-renowned Italian manufacturer and retailer of stovetop coffee (espresso) makers and small household electrical appliances. During his tenure at Bialetti, he was responsible for turning around the business by refocusing strategy, streamlining costs, and optimizing the product portfolio and retail presence. Prior to Bialetti, Mr. Cairoli served as General Manager of Star Alimentare, a major Italian food company, and successfully relaunched a historical brand. Additionally, he spent part of his career with Julius Meinl Italia and with Motorola Mobile Devices Italy. He also spent 10 years with Kraft Foods in Italy and the U.K. in various capacities. Mr. Cairoli holds a Bachelor’s degree in Economics from the Catholic University in Milan.
The Capitalization Report will soon be offering membership and reading the report is free!
Valuation of your business
VIP at events worldwide (this weekend was drinving a car 150 plus MPH at Amellia Island Concourse d’Eegance)
Networking events with other accredited investors and venture capitalist (this weekend was with owners of 10+ historic cars)
To learn about other membership and amazing things that happen to members contact via LinkedIn Jack D, Charllote F, or Sarah M ( Sarah@RHC21.fund ) anytime.
Asapp, Inc., a New York based artificial intelligence research-driven company, raised $120m with Dragoneer Investment Group and Fidelity Management & Research leading the deal (see below form more information)
Smartly.io acquired Viralspace.ai, a Palo Alto, Calif.-based digital advertising A.I. startup. Viralspace investors have included Lightspeed Venture Partners and Quest Venture Partners.
Wysa, a Boston MA-based company that provides an AI-powered mental health platform, raised $5.5M in Series A funding
Cervest, a London UK-based company which specializes in Al-powered Climat Intelligence (CI) platform, raised $30m in Series A funding
SymphonyRM, a Palo Alto, CA-based provider of AI powered patient engagement solutions for health systems, raised $25m in Series B funding
Heru Inc., a Miami FL-based company developer of wearable AI-powered vision diagnostics and augmentation software, raised $30m in Series A funding
(See List of 50+ Deals Below)
DEAL OVERVIEW ( Asapp, Inc. )
Developer of a machine learning software designed to make customer experiences more productive. The company’s AI platform augments, automates and enhances conversations with customers to close more deals while focusing on complex and data-rich problems, enabling customer care teams, salespeople and other organizations to be more efficient and effective while realizing their full potential and increase efficiency.
The CEO, Mr. Gustavo Sapoznik, is a Co-Founder and serves as Chief Executive Officer and Board Member at Asapp.
DEAL VALUATION ( Asapp, Inc. )
The company raised $120 million of Series C venture funding in a deal co-led by Dragoneer Investment Group and Fidelity Management & Research on May 19, 2021, putting the company’s pre-money valuation at $1.48 billion. Telstra Ventures, March Capital, Emergence Capital Partners, 40 North Ventures, Victor Wang, Marcus Westin, John Doerr, John Chambers, and Euclidean Capital also participated in the round. The funds will be used to increase investment in its AI Native® and Customer Experience Performance (CXP) platform.
DEAL (Recent AI Deals)
Sempra LNG
Sempra Energy reached a definitive agreement to sell a 20% stake in the company to Kohlberg Kravis Roberts for $3.37 billion on April 4, 2021. The transaction values the company at approximately $25.2 billion. Proceeds from the sale will be used to help fund growth across Sempra Energy’s $32 billion capital program, which is centered on its U.S. utilities and to further strengthen its balance sheet. The company is being actively tracked by PitchBook.
Nuvalent
The company raised $135 million of Series B venture funding in a deal led by Bain Capital Life Sciences on May 11, 2021, putting the company’s pre-money valuation at $335 million. Fairmount Funds Management, Driehaus Capital Management, Boxer Capital, Venrock, Deerfield Management, Fidelity Management & Research, Wellington Management, Viking Global Investors, Janus Henderson Investors, Avoro Capital and Logos Capital also participated in the round. The funds will be used to advance clinical trials and expand the discovery research pipeline. Previously, the company raised $50 million of Series A venture funding from Deerfield Management and other undisclosed investors on January 27, 2021, putting the company’s pre-money valuation at $20 million.
Neurelis
The company raised $114.76 million of Series D venture funding from Decheng Capital, Philos & Partners and Cormorant Asset Management on March 5, 2021, putting the company’s pre-money valuation at $350 million. Other undisclosed investors also participated in the round.
Ventyx Biosciences
The company raised $114 million of Series A1 venture funding in a deal led by venBio on March 9, 2021, putting the company’s pre-money valuation at $184 million. OrbiMed, Vivo Capital, Qiming Venture Partners, New Science Ventures, Third Point Ventures, RTW Investments, Janus Henderson Investors, Wellington Management, Cormorant Asset Management, Surveyor Capital and Farallon Capital Management also participated in the round. The funds will be used to accelerate the clinical development of immunology programs and advance preclinical programs against novel drug targets with the prolific drug discovery engine.
FogPharma
The company raised $107 million of Series C venture funding in a deal led by venBio on March 1, 2021, putting the company’s pre-money valuation at $150 million. GV, PagsGroup, The Invus Group, HBM Healthcare Investments, 6 Dimensions Capital, Deerfield Management, Cormorant Asset Management, Farallon Capital Management, Blue Pool Capital, Casdin Capital and T. Rowe Price also participated in the round. The funds will be used to advance its lead, only-in-class Helicon peptides aimed at addressing substantial cancer patient populations into clinical development.
Tripledot
The company raised GBP 58.93 million of Series A venture funding from Access Industries, Lightspeed Venture Partners and Eldridge (Greenwich) on April 8, 2021, putting the pre-money valuation at GBP 260 million. The funds will be used to expand operations by acquiring studios and rollout the next generation of titles.
Rapid Micro Biosystems
The company raised $81 million of Series D1 venture funding in a deal led by D1 Capital Partners on March 16, 2021, putting the company’s pre-money valuation at $625 million. Bain Capital, Ally Bridge Group, Endeavour Vision, Xeraya Capital, Quaker Partners, Longitude Capital, Asahi Kasei Medical, BlackRock, T. Rowe Price, Adage Capital Management, Sunley House Capital Management and CaaS Capital Management also participated in the round. The funds will be used to accelerate the company’s growth.
Aura Biosciences
The company raised $80 million of Series E venture funding in a deal led by Matrix Capital Management and Surveyor Capital on March 22, 2021, putting the company’s pre-money valuation at $200 million. Chiesi Ventures, Lundbeckfond Ventures, Medicxi, Ysios Capital, Advent Life Sciences, Arix Bioscience, Columbus Venture Partners, Velosity Capital, Rock Springs Capital and Adage Capital Management also participated in the round. The funds will be used to advance the clinical development of its VDC technology platform, including the pivotal Phase 3 program for AU-011, its lead candidate in development for the first-line treatment of choroidal melanoma, and ongoing research for additional programs in ocular oncology, as well as expanding the VDC technology into bladder cancer, the first non-ophthalmic solid tumor indication.
ComplyAdvantage
The company raised $70 million of Series C venture funding in a deal led by Ontario Teachers’ Pension Plan on May 20, 2021, putting the company’s pre-money valuation at $296.26 million. The Goldman Sachs Group and 9 other investors also participated in the round. The company intends to use the fund to accelerate the development of the company’s industry-leading data and suite of products to serve institutions with diverse clients and complex risk exposure.
Vyond
The company raised $50 million of venture funding in a deal led by PeakSpan Capital on April 16, 2021, putting the company’s pre-money valuation at $150 million. The funds will be used to continue its history of high caliber innovation velocity and dedication to delivering superior customer success at scale, for the most demanding customers across the globe.
Mineralys
The company raised $40 million of Series A venture funding in a deal led by HBM Healthcare Investments and Samsara BioCapital on April 6, 2021, putting the company’s pre-money valuation at $37.5 million. Adams Street Partners and Catalys Pacific also participated in the round. The company intends to use the fund to complete a phase 2 proof-of-concept study for its lead experimental hypertension treatment, MLS-101 and for preparatory work for late-stage testing of the therapy.
You must be logged in to post a comment.